December 13, 2006Open Access

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Alan Sandler

Robert J. Gray

Michael C. Perry

Journals

New England Journal of Medicine

Actions

Institutions

Johns Hopkins University

University of Wisconsin–Madison

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study